Lyfgenia
Bluebird’s Struggles with Sickle Cell Gene Therapy Launch Impact Financial Stability
Bluebird Bio, sickle cell disease, gene therapy, Lyfgenia, loan rework, cash runway, financial stability
CMS to Increase Reimbursement for New Sickle Cell Gene Therapies through Outcomes-Based Agreements
CMS (Centers for Medicare & Medicaid Services), Sickle Cell Gene Therapies, Increased Reimbursement, Outcomes-Based Agreements (OBAs), Cell and Gene Therapy (CGT) Access Model, Medicaid Access, Casgevy, Lyfgenia, Fertility Preservation Services, Equitable Access, Administrative Burden Reduction